Insider Selling: Exact Sciences Co. (NASDAQ:EXAS) Insider Sells 1,879 Shares of Stock

Exact Sciences Co. (NASDAQ:EXASGet Free Report) insider Jacob A. Orville sold 1,879 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $56.89, for a total transaction of $106,896.31. Following the completion of the sale, the insider now owns 11,754 shares of the company’s stock, valued at $668,685.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Exact Sciences Price Performance

EXAS stock traded down $0.59 during trading on Wednesday, hitting $56.31. The company had a trading volume of 1,628,300 shares, compared to its average volume of 1,976,769. The business has a 50 day moving average of $65.93 and a 200 day moving average of $68.45. The firm has a market capitalization of $10.22 billion, a price-to-earnings ratio of -49.39 and a beta of 1.27. The company has a current ratio of 2.32, a quick ratio of 2.07 and a debt-to-equity ratio of 0.74. Exact Sciences Co. has a fifty-two week low of $56.05 and a fifty-two week high of $100.77.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The business had revenue of $646.89 million during the quarter, compared to analysts’ expectations of $638.83 million. During the same period last year, the firm posted ($0.72) earnings per share. The business’s revenue was up 17.0% on a year-over-year basis. As a group, research analysts predict that Exact Sciences Co. will post -0.95 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Canaccord Genuity Group decreased their price target on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday. Guggenheim assumed coverage on Exact Sciences in a report on Thursday, December 14th. They issued a “buy” rating and a $90.00 price objective for the company. Benchmark raised Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price target on the stock in a report on Tuesday, January 2nd. Finally, William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $99.31.

View Our Latest Stock Report on Exact Sciences

Institutional Trading of Exact Sciences

Several institutional investors have recently modified their holdings of EXAS. Segall Bryant & Hamill LLC lifted its holdings in Exact Sciences by 4.7% in the 2nd quarter. Segall Bryant & Hamill LLC now owns 3,315 shares of the medical research company’s stock valued at $311,000 after acquiring an additional 150 shares during the last quarter. Kestra Advisory Services LLC raised its holdings in shares of Exact Sciences by 0.9% in the 2nd quarter. Kestra Advisory Services LLC now owns 17,195 shares of the medical research company’s stock worth $1,615,000 after purchasing an additional 154 shares in the last quarter. Harbour Investments Inc. raised its holdings in shares of Exact Sciences by 0.6% in the 1st quarter. Harbour Investments Inc. now owns 26,279 shares of the medical research company’s stock worth $1,782,000 after purchasing an additional 162 shares in the last quarter. Strategic Blueprint LLC lifted its stake in Exact Sciences by 3.1% during the third quarter. Strategic Blueprint LLC now owns 5,449 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 163 shares during the last quarter. Finally, Green Alpha Advisors LLC boosted its holdings in Exact Sciences by 3.5% during the third quarter. Green Alpha Advisors LLC now owns 4,893 shares of the medical research company’s stock worth $334,000 after buying an additional 165 shares in the last quarter. Institutional investors and hedge funds own 89.13% of the company’s stock.

Exact Sciences Company Profile

(Get Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

See Also

Insider Buying and Selling by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.